A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of VAY736 in Autoimmune Hepatitis
Phase of Trial: Phase II/III
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Ianalumab (Primary)
- Indications Autoimmune hepatitis
- Focus Therapeutic Use
- Acronyms AMBER
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 05 Dec 2018 Planned End Date changed from 30 Dec 2020 to 24 Nov 2022.
- 05 Dec 2018 Planned primary completion date changed from 30 Dec 2020 to 29 Jul 2022.
- 13 Nov 2018 Trial design presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases